Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02877615




Registration number
NCT02877615
Ethics application status
Date submitted
20/07/2016
Date registered
24/08/2016
Date last updated
11/03/2020

Titles & IDs
Public title
Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event
Scientific title
Randomized Efficacy and Safety Trial With Oral S 44819 After Recent Ischemic Cerebral Event. International, Multi-centre, Randomized, Doubleblind Placebo-controlled Phase II Study. (RESTORE BRAIN Study)
Secondary ID [1] 0 0
2016-001005-16
Secondary ID [2] 0 0
CL2-44819-004
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Post Stroke Recovery 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - S 44819 150 mg twice a day
Treatment: Drugs - S 44819 300 mg twice a day
Treatment: Drugs - Placebo

Experimental: S 44819 150 mg twice a day -

Experimental: S 44819 300 mg twice a day -

Placebo comparator: Placebo -


Treatment: Drugs: S 44819 150 mg twice a day
One sachet of S 44819 150 mg and one sachet of placebo twice a day

Treatment: Drugs: S 44819 300 mg twice a day
Two sachets of S 44819 150 mg twice a day

Treatment: Drugs: Placebo
Two sachets of placebo twice a day
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Modified Rankin Scale (mRS)
Timepoint [1] 0 0
Up to 90 days
Secondary outcome [1] 0 0
National Institutes of Health Stroke Scale (NIHSS) total score
Timepoint [1] 0 0
Selection visit Day 0 Day 5 Day 30 Day 60 Day 90 Day 105
Secondary outcome [2] 0 0
Barthel Index (BI) total score
Timepoint [2] 0 0
Day 30 Day 60 Day 90 Day 105
Secondary outcome [3] 0 0
Montreal Cognitive Assessment scale (Moca) total score
Timepoint [3] 0 0
Day 30 Day 90
Secondary outcome [4] 0 0
Trail Making Test (TMT) time for part A
Timepoint [4] 0 0
Day 30 Day 90
Secondary outcome [5] 0 0
Adverse events
Timepoint [5] 0 0
Through study completion, an average of 3 months
Secondary outcome [6] 0 0
Suicidal ideation and suicidal behavior using the Columbia-Suicide Severity Rating Scale (C-SSRS)
Timepoint [6] 0 0
Day 5 Day 30 Day 60 Day 90 Day 105
Secondary outcome [7] 0 0
Body weight
Timepoint [7] 0 0
Selection visit Day 30 Day 60 Day 90 Day 105
Secondary outcome [8] 0 0
Vital signs (supine for Systolic and Diastolic Blood Pressure)
Timepoint [8] 0 0
Selection visit Day 0 Day 5 Day 30 Day 60 Day 90 Day 105
Secondary outcome [9] 0 0
12 lead-ECG
Timepoint [9] 0 0
Day 0 Day 5 Day 30 Day 60 Day 90 Day 105
Secondary outcome [10] 0 0
Trail Making Test (TMT) time for part B
Timepoint [10] 0 0
Day 30 Day 90

Eligibility
Key inclusion criteria
Inclusion criteria :

* Patients aged between 18 and 85 years (both inclusive)
* Acute ischemic stroke that occured between 72 hours (3 days) and 192 hours (8 days) (both inclusive) before inclusion
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria :

* Any non-selection criteria, which could have occurred after the selection visit
* Positive urinary or blood pregnancy test (for female patients of child bearing potential)
* Any clinically significant findings from the local laboratory test likely to interfere with the ability to participate in the study and / or with the study outcome
* Severe renal impairment detected in the local laboratory test
* Severe hepatic impairment or liver enzymes abnormalities found in the local laboratory test
* Stroke due to cerebral venous thrombosis
* Brain MRI showing a severe microangiopathy
* Brain imaging showing an acute haemorrhagic stroke or a symptomatic haemorrhagic transformation of the brain infarct
* Qualifying ischemic cerebral event older than 192 hours at inclusion
* Any clinically relevant abnormalities detected during the examinations likely to interfere with study procedures or study outcome,
* Repeated prolongation of ECG QTcF
* Patient or authorised representative refusing to attend study visits or to take part in the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/12/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/03/2019
Sample size
Target
Accrual to date
Final
585
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Adelaide Hospital Department of Neurology - Adelaide
Recruitment hospital [2] 0 0
Sunshine Coast Hospital - Birtinya
Recruitment hospital [3] 0 0
Monash Medical Centre Department of Neurology - Clayton
Recruitment hospital [4] 0 0
Lyell McEwin Hospital Neurology Department - Elizabeth Vale
Recruitment hospital [5] 0 0
Gosford Hospital Neurosciences Department - Gosford
Recruitment hospital [6] 0 0
Austin Health Neurology Department - Heidelberg
Recruitment hospital [7] 0 0
Royal Brisbane & Women's Hospital Department of Neurology - Herston
Recruitment hospital [8] 0 0
Alfred Health - Melbourne
Recruitment hospital [9] 0 0
Royal Melbourne Hospital Department of Neurology - Parkville
Recruitment hospital [10] 0 0
Gold Coast University Hospital - Southport
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
4575 - Birtinya
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [5] 0 0
2250 - Gosford
Recruitment postcode(s) [6] 0 0
VIC 3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
4029 - Herston
Recruitment postcode(s) [8] 0 0
3004 - Melbourne
Recruitment postcode(s) [9] 0 0
3050 - Parkville
Recruitment postcode(s) [10] 0 0
QLD 4215 - Southport
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Brugge
Country [2] 0 0
Belgium
State/province [2] 0 0
Edegem
Country [3] 0 0
Belgium
State/province [3] 0 0
Hasselt
Country [4] 0 0
Belgium
State/province [4] 0 0
Leuven
Country [5] 0 0
Belgium
State/province [5] 0 0
Liege
Country [6] 0 0
Belgium
State/province [6] 0 0
Tielt
Country [7] 0 0
Brazil
State/province [7] 0 0
Botucatu
Country [8] 0 0
Brazil
State/province [8] 0 0
Joinville
Country [9] 0 0
Brazil
State/province [9] 0 0
Matão
Country [10] 0 0
Brazil
State/province [10] 0 0
Porto Alegre
Country [11] 0 0
Brazil
State/province [11] 0 0
Ribeirao Preto
Country [12] 0 0
Brazil
State/province [12] 0 0
Ribeirão Preto
Country [13] 0 0
Brazil
State/province [13] 0 0
Rio de Janeiro
Country [14] 0 0
Brazil
State/province [14] 0 0
Sao Paulo
Country [15] 0 0
Canada
State/province [15] 0 0
Edmonton
Country [16] 0 0
Canada
State/province [16] 0 0
Greenfield Park
Country [17] 0 0
Canada
State/province [17] 0 0
Montreal
Country [18] 0 0
Canada
State/province [18] 0 0
Saint John
Country [19] 0 0
Czechia
State/province [19] 0 0
Brno
Country [20] 0 0
Czechia
State/province [20] 0 0
Jihlava
Country [21] 0 0
Czechia
State/province [21] 0 0
Praha
Country [22] 0 0
France
State/province [22] 0 0
Bordeaux
Country [23] 0 0
France
State/province [23] 0 0
Corbeil-essonnes
Country [24] 0 0
France
State/province [24] 0 0
Creteil
Country [25] 0 0
France
State/province [25] 0 0
Le Kremlin-Bicêtre
Country [26] 0 0
France
State/province [26] 0 0
Lille
Country [27] 0 0
France
State/province [27] 0 0
Montpellier
Country [28] 0 0
France
State/province [28] 0 0
Paris
Country [29] 0 0
France
State/province [29] 0 0
Poitiers
Country [30] 0 0
Germany
State/province [30] 0 0
Altenburg
Country [31] 0 0
Germany
State/province [31] 0 0
Bad Neustadt An Der Saale
Country [32] 0 0
Germany
State/province [32] 0 0
Berlin
Country [33] 0 0
Germany
State/province [33] 0 0
Erlangen
Country [34] 0 0
Germany
State/province [34] 0 0
Essen
Country [35] 0 0
Germany
State/province [35] 0 0
Mainz
Country [36] 0 0
Germany
State/province [36] 0 0
Minden
Country [37] 0 0
Germany
State/province [37] 0 0
Siegen
Country [38] 0 0
Germany
State/province [38] 0 0
Tübingen
Country [39] 0 0
Germany
State/province [39] 0 0
ULM
Country [40] 0 0
Hungary
State/province [40] 0 0
Budapest
Country [41] 0 0
Hungary
State/province [41] 0 0
Gyor
Country [42] 0 0
Hungary
State/province [42] 0 0
Kaposvár
Country [43] 0 0
Hungary
State/province [43] 0 0
Kistarcsa
Country [44] 0 0
Hungary
State/province [44] 0 0
Miskolc
Country [45] 0 0
Hungary
State/province [45] 0 0
Nagykanizsa
Country [46] 0 0
Hungary
State/province [46] 0 0
Nyiregyhaza
Country [47] 0 0
Hungary
State/province [47] 0 0
Pecs
Country [48] 0 0
Hungary
State/province [48] 0 0
Sopron
Country [49] 0 0
Hungary
State/province [49] 0 0
Szeged
Country [50] 0 0
Italy
State/province [50] 0 0
Lecce
Country [51] 0 0
Italy
State/province [51] 0 0
Milano
Country [52] 0 0
Italy
State/province [52] 0 0
Negrar
Country [53] 0 0
Italy
State/province [53] 0 0
Pozzilli
Country [54] 0 0
Italy
State/province [54] 0 0
Rome
Country [55] 0 0
Korea, Republic of
State/province [55] 0 0
Busan
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Daegu
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Gwangju
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Seongnam
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Seoul
Country [60] 0 0
Netherlands
State/province [60] 0 0
Heerlen
Country [61] 0 0
Netherlands
State/province [61] 0 0
Nijmegen
Country [62] 0 0
Netherlands
State/province [62] 0 0
Rotterdam
Country [63] 0 0
Netherlands
State/province [63] 0 0
Zwolle
Country [64] 0 0
Poland
State/province [64] 0 0
Chelm
Country [65] 0 0
Poland
State/province [65] 0 0
Gdansk
Country [66] 0 0
Poland
State/province [66] 0 0
Katowice
Country [67] 0 0
Poland
State/province [67] 0 0
Konskie
Country [68] 0 0
Poland
State/province [68] 0 0
Lodz
Country [69] 0 0
Poland
State/province [69] 0 0
Lublin
Country [70] 0 0
Poland
State/province [70] 0 0
Rybnik
Country [71] 0 0
Poland
State/province [71] 0 0
Sandomierz
Country [72] 0 0
Poland
State/province [72] 0 0
Warszawa
Country [73] 0 0
Spain
State/province [73] 0 0
Albacete
Country [74] 0 0
Spain
State/province [74] 0 0
Badalona
Country [75] 0 0
Spain
State/province [75] 0 0
Barcelona
Country [76] 0 0
Spain
State/province [76] 0 0
Girona
Country [77] 0 0
Spain
State/province [77] 0 0
Madrid
Country [78] 0 0
Spain
State/province [78] 0 0
San Sebastian
Country [79] 0 0
Spain
State/province [79] 0 0
Sevilla
Country [80] 0 0
Spain
State/province [80] 0 0
Valencia
Country [81] 0 0
Sweden
State/province [81] 0 0
Hassleholm
Country [82] 0 0
Sweden
State/province [82] 0 0
Linkoping
Country [83] 0 0
Sweden
State/province [83] 0 0
Skovde
Country [84] 0 0
Sweden
State/province [84] 0 0
Stockholm
Country [85] 0 0
Sweden
State/province [85] 0 0
Uppsala
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Bath
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Glasgow
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Harrow
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Leicester
Country [90] 0 0
United Kingdom
State/province [90] 0 0
London
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Nottingham
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Poole
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Sheffield
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Stoke on Trent

Funding & Sponsors
Primary sponsor type
Other
Name
Institut de Recherches Internationales Servier
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
ADIR, a Servier Group company
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the efficacy and safety of S 44819 in enhancing functional recovery after an ischemic stroke.
Trial website
https://clinicaltrials.gov/study/NCT02877615
Trial related presentations / publications
Chabriat H, Bassetti CL, Marx U, Picarel-Blanchot F, Sors A, Gruget C, Saba B, Wattez M, Audoli ML, Hermann DM. Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study. Trials. 2020 Feb 3;21(1):136. doi: 10.1186/s13063-020-4072-2.
Chabriat H, Bassetti CL, Marx U, Audoli-Inthavong ML, Sors A, Lambert E, Wattez M, Hermann DM; RESTORE BRAIN study investigators. Safety and efficacy of GABAA alpha5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2020 Mar;19(3):226-233. doi: 10.1016/S1474-4422(20)30004-1.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02877615